September 15, 2012
Johnson & Johnson, Pfizer, and Merck are part of the Dow Jones Industrial Average Index, and Merck has been the best health-care performer so far in 2012. Its year-to-date 18% share price appreciation beats out its rival drug makers, and even the Dow's collective 11% rise.
In the video below, healthcare bureau chief Brenton Flynn and analyst Max Macaluso discuss the driving force behind Merck's recent success, a few things that investors should be watching in upcoming quarters, and the German drugmaker that shares Merck's name, but operates as a separate company.
Merck has been on the upswing of late, but it didn’t make the Motley Fool’s list of the The 3 Dow Stocks Dividend Investors Need. This is a great resource for investors looking to boost their portfolios with long-term Blue Chip stocks. This report is absolutely free -- just click here and get your copy today.